NorthShore University HealthSystem and GoPath Laboratories Partner to Offer the Most Comprehensive Inherited Risk Assessment for Prostate Cancer with PROSTATENOW

NorthShore University HealthSystem and GoPath Laboratories has announced a novel partnership to launch a new genetics test that assesses the inherited risk for prostate cancer using three methods: family history, rare pathogenic mutations and genetic risk score.
[NorthShore University HealthSystem (PR Newswire, LLC.)]
Press Release
Bookmark

No account yet? Register

0
Share

City of Hope Enters Licensing Agreements with CytoImmune Therapeutics Inc. to Develop Portfolio of Chimeric Antigen Receptor-Natural Killer Therapies

City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cells to tumors.
[CytoImmune Therapeutics, Inc. (BusinessWire, Inc)]
Press Release
Bookmark

No account yet? Register

0
Share

Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research

Volastra Therapeutics announced it will collaborate with Microsoft to develop tools that help detect drivers of cancer metastasis. The collaboration will develop automated machine learning tools capable of rapidly and accurately integrating insights across multiple datasets, including pathology slides and 3D tumor-derived organoids.
[Volastra Therapeutics (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

BeiGene Provides Update on Phase II Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress

-BeiGene, Ltd. announced that the Phase II trial evaluating BRUKINSA® in patients hospitalized with respiratory symptoms of COVID-19, requiring supplemental oxygen without mechanical ventilation, did not meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen as compared to placebo.
[BeiGene, Ltd. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

FDA Approves Trodelvy® the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Gilead Sciences, Inc. announced that the FDA has granted full approval to Trodelvy® for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.
[Gilead Sciences, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase I Study of ADXS-504 for the Treatment of Early Prostate Cancer

Advaxis, Inc.has announced an agreement with Columbia University Irving Medical Center to fund a Phase I clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study, expected to begin in Q2 2021, will be the first clinical evaluation of ADXS-504, Advaxis’ off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
[Advaxis, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Aspect Biosystems and JSR Corporation Enter Collaboration to Develop Bioprinted Vascularized Tissues for Regenerative Medicine

Aspect Biosystems announced a new joint development program with JSR Corporation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D bioprinting platform with JSR’s advanced materials technology to develop implantable vascularized tissues for kidney regeneration and other applications in regenerative medicine.
[Aspect Biosystems, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

ERC-USA Announces FDA Recommendation for Early Termination of Phase II Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma

ERC-USA and the University of California, Irvine has announced that the FDA has recommended early termination of the onging Phase II clinical trial titled ERC1671/GM-CSF/Cyclophosphamide for the treatment of glioblastoma.
[ERC-USA (Globe Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

ClearPoint Neuro, Inc. congratulated uniQure N.V. on the early completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 being conducted in the United States for the treatment of early-stage Huntington’s disease.
[ClearPoint Neuro, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage II of Phase II Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.
[Bio-Path Holdings, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem® for Acute Respiratory Distress Syndrome in Japan

Athersys, Inc. announced that its partner HEALIOS K.K. has completed enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem® in patients with acute respiratory distress syndrome (ARDS) caused by pneumonia.
[Athersys, Inc]
Press Release
Bookmark

No account yet? Register

0
Share
Share